



Horizon 2020 'Health, demographic change and wellbeing'

Grigorij Kogan, PhD, DSc
Medical Research and the Challenge of Ageing Unit
Health Research Directorate
Research & Innovation DG
European Commission



HORIZON 2020

Information Day -Horizon 2020
'Health, demographic change and wellbeing'
Bratislava, May 30, 2014

Building on experience

FP7 'Health' – the largest multi-national fund...

- ...for collaborative research, global consortia, and public-private co-operation
- ...to fund excellent applied health and ageing research and innovation
- ...to bring together leading players from Europe and across the globe
- ...to tackle key European and global health challenges



What is Horizon 2020



**The EU's 2014-20 programme
for research & innovation**

**A core part of Europe 2020,
Innovation Union &
European Research Area**

- Responding to the economic crisis to invest in future jobs and growth
- Addressing people's concerns about their livelihoods, safety and environment
- Strengthening the EU's global position in research, innovation and technology

Horizon 2020 - what's new?

- **A single programme** bringing together three separate programmes/initiatives*
- **Coupling research to innovation** – from research to retail, all forms of innovation
- **Focus on societal challenges** facing European society e.g. health and ageing, clean energy and transport
- **Simplified access**, for all companies, universities, institutes in all EU countries and beyond

* The 7th Research Framework Programme (FP7), innovation aspects of Competitiveness and Innovation Framework Programme (CIP), EU contribution to the European Institute of Innovation and Technology (EIT)

Three priorities



Excellent science

Proposed funding
(million EUR, 2014-2020)

<i>European Research Council (ERC)</i> Frontier research by the best individual teams	13 095
<i>Future and Emerging Technologies</i> Collaborative research to open new fields of innovation	2 696
<i>Marie Skłodowska-Curie actions (MSCA)</i> Opportunities for training and career development	6 162
<i>Research infrastructures (including e-infrastructure)</i> Ensuring access to world-class facilities	2 488

Industrial leadership

Proposed funding
(million EUR, 2014-2020)*

<i>Leadership in enabling and industrial technologies (LEITs)</i> (ICT, nanotechnologies, materials, biotechnology, manufacturing, space)	13 557
<i>Access to risk finance</i> Leveraging private finance and venture capital for research and innovation	2 842
<i>Innovation in SMEs</i> Fostering all forms of innovation in all types of SMEs	616 + complemented by expected 20% of budget of societal challenges + LEITs and 'Access to risk finance' with strong SME focus

* All funding figures in this presentation are subject to the pending Multiannual Financial Framework Regulation by the EP and the Council

Societal challenges

Health Priority in FP7 Cooperation programme: € 6.1 billion

22% increase

Proposed funding
(million EUR, 2014-2020)

Health, demographic change and wellbeing	7 472
Food security, sustainable agriculture and forestry, marine and maritime and inland water research and the Bioeconomy	3 851
Secure, clean and efficient energy	5 931
Smart, green and integrated transport	6 339
Climate action, environment, resource efficiency and raw materials	3 081
Inclusive, innovative and reflective societies	1 310
Secure societies	1 695
<i>Science with and for society</i>	<i>462</i>
<i>Spreading excellence and widening participation</i>	<i>816</i>

Strategic Initiatives



Innovative Medicines Initiative 2
www.imi.europa.eu



**European Innovation Partnership
on Active and Healthy Ageing**
<https://webgate.ec.europa.eu/eipaha>



Active and Assisted Living 2
www.aal-europe.eu



**European & Developing Countries
Clinical Trials Partnership (EDCTP2)**
www.edctp.org

The challenges



- **Ageing population**
- **Increased disease burden**
- **Unsustainable and unequal health & care systems**
- **Health & care sector under pressure to reform**

Horizon 2020 - Societal Challenge 1



- **Translating science to benefit citizens**
- **Improve health outcomes**
- **Support a competitive health & care sector**
- **Test and demonstrate new health & care models, approaches and tools**
- **Promote healthy and active ageing**

Do also look elsewhere! EU support of health related research & innovation is not limited to Societal Challenge 1

A new approach

Challenge-driven

Broad topics

Less prescriptive topic texts

Two-year work programme

Stronger focus on end users

More opportunities for SMEs

- **Integrated approach** - around 20% of the total budget for societal challenges and LEITs to go to SMEs
- **Simplification** of particular benefit to SMEs (e.g. single entry point)
- A **new SME instrument** will be used across all societal challenges as well as for the LEITs
- A dedicated activity for research-intensive SMEs in '**Innovation in SMEs**'
- '**Access to risk finance**' will have a strong SME focus (debt and equity facility)

Getting you started faster

- **Single set of** simpler and more coherent participation **rules**
- New **balance between trust & control**
- Just **two funding rates** for different beneficiaries and activities
- **Single flat rate** to calculate overhead or «indirect costs»
- **Forthcoming financial regulation** will make things simpler
- **time-to-grant of 8 months**
(exceptions for the ERC and in duly justified cases)



International cooperation

- A priority
- Key goal: enhancing and focusing international cooperation in terms of areas and partners
- Horizon 2020 is open to participation from across the world
- Wanted: more involvement of international partners!
- Targeted actions across the entire programme
- Horizon 2020 Regulation and Rules for Participation apply



General opening

- Horizon 2020 is **open to participation from across the world**
- **Automatic funding:**
 - Member States (including overseas departments and overseas territories)
 - Associated Countries
 - exhaustive list of countries in annex to work programme (but: no longer BRIC + Mexico in this list!)
- Participants from other countries only funded in **exceptional cases:**
 - when provision is made in the call text
 - bilateral agreement (e.g. Health challenge – NIH)
 - when the Commission deems it essential (case by case assessment)



Targeted actions

- **Targeted international cooperation activities** across Horizon 2020: area for cooperation and partner specified upfront
- Areas identified based on analysis of a **set of criteria** to ensure common interest and mutual benefit:
 - Research and innovation excellence
 - Framework conditions/access to markets
 - Contribution to international commitments
 - Frameworks to engage in cooperation and lessons learned
- Differentiation by **countries/regions**: enlargement/neighbourhood/EFTA, industrialised and emerging countries, developing countries
- International cooperation as part of **strategic planning** for each part of Horizon 2020
- Result: **roadmaps** for international cooperation with international partners (to be published early 2014)



Implementation in Horizon 2020

- **Regular calls for proposals:**
 - **topics inviting projects** where third country participation is required and/or encouraged
 - **topics stimulating networking** between existing projects
- **Joint initiatives of Union and third countries:**
 - bilateral coordinated/joint calls
 - multi-lateral initiatives
 - contribution of Union to third country/international organisations
 - ERA-Net



Societal Challenge 1 "Health, Demographic Change and Wellbeing" call 2014-2015

All information about the published or future calls can be found at:

<http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/index.html>

The call for 2014-2015 has been published on December 11, 2013. The two-stage submission call has been launched and the first stage evaluations have taken place with the results having been acknowledged to the applicants. Deadline for submission of the second stage proposals is August 19, 2014.

SC1 Call 2014-2015

HORIZON 2020 – WORK PROGRAMME 2014-2015

Health, demographic change and wellbeing

Personalising health and care	7	Co-ordination activities	61
Understanding health, ageing and disease.....	7	HCO 1 – 2014: Support for the European Innovation Partnership on Active and Healthy Ageing.....	61
PHC 1 – 2014: Understanding health, ageing and disease: determinants, risk factors and pathways.....	7	HCO 2 – 2014: Joint Programming: Coordination Action for the Joint Programming Initiative (JPI) "More Years, Better Lives - the Challenges and Opportunities of Demographic Change" ..	62
PHC 2 – 2015: Understanding diseases: systems medicine.....	8	HCO 3 – 2015: Support for the European Reference Networks: Efficient network modelling and validation.....	64
PHC 3 - 2015: Understanding common mechanisms of diseases and their relevance in co-morbidities.....	9	HCO 4 – 2014: Support for international infectious disease preparedness research.....	66
Integrated, sustainable, citizen-centred care.....	33	HCO 5 – 2014: Global Alliance for Chronic Diseases: prevention and treatment of type 2 diabetes.....	67
PHC 23 – 2014: Developing and comparing new models for safe and efficient, prevention oriented health and care systems:.....	33	Other actions	89
PHC 24 – 2015: Piloting personalised medicine in health and care systems	34	HOA 1 – 2014/2015: Subscription fee: Human Frontier Science Programme Organisation.....	89
PHC 25 – 2015: Advanced ICT systems and services for Integrated Care.....	35	HOA 2 – 2014/2015: Tenders for programme evaluation, studies and impact assessment and for conferences, events and outreach activities.....	89
PHC 26 – 2014: Self-management of health and disease: citizen engagement and mHealth	37	HOA 3 – 2014/2015: Presidency events - eHealth.....	90
PHC 27 – 2015: Self-management of health and disease and patient empowerment supported by ICT	40	HOA 4 – 2014/15: Independent experts assisting in proposal evaluations and project reviews... ..	90
		HOA 5 – 2014: Grant to the Global Alliance for Chronic Diseases	90

Examples of the topics

PHC 1 – 2014: Understanding health, ageing and disease: determinants, risk factors and pathways

Specific challenge: The development and preservation of good health, and the occurrence and evolution of common diseases and disabilities result from varying degrees of interaction between the genetic make-up of individual human beings and behavioural, environmental (including endocrine disruptors), occupational, nutritional and other modifiable lifestyle factors. This applies from the earliest stages of development throughout life.

Understanding these factors, their interactions and the extent to which they contribute to health preservation and/or to disease development is important for the development of preventive and therapeutic measures supporting good health, prolonged active independence and a productive working life, not least in the context of changing demographic patterns and the ageing of the European population. In particular, proposals should contribute to improving risk identification and validation, and will allow better diagnosis, risk-based prevention strategies and policies.

Scope:

EITHER:

- i. The identification of health trends and determinants, their validation, and the validation of risk factors for disease and disability, through the generation, integration and validation of data derived from relevant disciplines (e.g. molecular, behavioural, nutritional, clinical, social and environmental epidemiology; exposure sciences; genetics, epigenetics, etc.). This should involve the exploitation of existing cohorts and longitudinal studies and the assessment of the necessity to establish new ones, as well as where relevant, the valorisation of knowledge gained from population-based bio-banks.

OR:

- ii. The identification of determinants and pathways characteristic of healthy and active ageing (from early stages of development onwards) and of health deterioration caused by time, disease accumulation and the abovementioned risk factors and their interactions.

In both cases, sex and gender differences should be taken into account.

The Commission considers that proposals requesting a contribution from the EU of between EUR 4 and 6 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

11/11/2014

PHC 13 – 2014: New therapies for chronic non-communicable diseases

Specific challenge: Chronic non-communicable diseases represent a significant burden on individuals and healthcare systems. Innovative, cost effective therapeutic approaches are required to provide the best quality of care when prevention fails. While a considerable amount of knowledge has been generated by biomedical research in recent years, the development of new therapies is stagnating, in part due to a lack of clinical validation.

Scope: Clinical trial(s) supporting proof of concept in humans to assess the potential clinical efficacy of the novel therapeutic concept(s) and / or optimisation of available therapies (e.g. drug repurposing). The application may build on pre-existing pre-clinical research and additional results from large scale databases. A concise feasibility assessment justified by available published and preliminary results and supporting data should also be provided. Considerations of effectiveness and potential clinical benefit (possibly including real world data) should be integrated in the application if relevant.

The Commission considers that proposals requesting a contribution from the EU of between EUR 4 and 6 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected impact: This should provide:

- New therapeutic strategies, adapted where relevant to the differing needs of men and women, with the highest potential to generate advances in clinical practice for chronic diseases, including multi- or comorbidity, ready for further development.
- Early exclusion of candidate strategies unlikely to succeed.
- Contribute to the improvement of the therapeutic outcome of major chronic health issues with significant impact on burden of diseases both for individual patients and for health care systems.

Type of action: Research and innovation actions

2015 Calls and general conditions


TOPICS OPEN IN 2015

PHC 2 – 2015: Understanding diseases: systems medicine	8
PHC 3 - 2015: Understanding common mechanisms of diseases and their relevance in co-morbidities.....	9
Effective health promotion, disease prevention, preparedness and screening.....	10
PHC 4 – 2015: Health promotion and disease prevention: improved inter-sector co-operation for environment and health based interventions	10
PHC 5 – 2014: Health promotion and disease prevention: translating ‘omies’ into stratified approaches	11
PHC 9 – 2015: Vaccine development for poverty-related and neglected infectious diseases: HIV/AIDS	16
PHC 11 – 2015: Development of new diagnostic tools and technologies: <i>in vivo</i> medical imaging technologies.....	19
PHC 14 – 2015: New therapies for rare diseases	23
PHC 18 – 2015: Establishing effectiveness of health care interventions in the paediatric population.....	28
PHC 22 – 2015: Promoting mental wellbeing in the ageing population	32
Integrated, sustainable, citizen-centred care.....	33
PHC 23 – 2014: Developing and comparing new models for safe and efficient, prevention oriented health and care systems:	33


CONDITIONS FOR THE CALLS (Work Programme 2014-2014 p. 54)

	2014 EUR million	2015 EUR million	
PHC 1 - 2014	54.00		Two stage
PHC 2 - 2015		36.00	Two stage
PHC 3 - 2015		30.00	Two stage
PHC 4 - 2015		18.00	Two stage
PHC 5 - 2014	24.00		Two stage
PHC 6 - 2014	15.00		Two stage
PHC 10 - 2014	48.00		Two stage
PHC 11 - 2015		47.00	Two stage
PHC 12 – 2014 /2015	66.10 out of which 6.61 for phase 1 58.17 for phase 2 1.32 for mentoring and coaching support and phase 3	45.00 <i>Out of which</i> <i>4.50 for phase 1</i> <i>39.60 for phase 2</i> <i>0.90 for mentoring and coaching support and phase 3</i>	SME instrument
Single stage for both phase 1 and phase 2.			

Stage 1 evaluation process – **simplified** approach



Overview of the Evaluation process 2nd Stage



Consensus meetings

(in Brussels)

Evaluators meet to:

Discuss on basis of all individual assessment reports (including absent evaluators)

Agree on consensus marks and comments for each criteria. These must be aligned:


- positive comments for high score
- negative comments for low score

Give clear explanations for proposed changes (if any)

Only proposals passing all thresholds go to the next step (panel meeting for ranking).

Consensus meeting

Consensus meeting outcome



Consensus meetings

Role of the “rapporteur”

One evaluator will be nominated as rapporteur for each proposal.
He/she will:

- Ensure that IARs of absent remote evaluators are taken into account
- Note the consensus marks and comments in the Consensus Report (CR)
- Circulate and draft the CR with the other evaluators, signs it and ask for signature of the moderator
- Finalise the consensus report in RIVET only when agreed and approved by Commission moderator

Invitation to register and become an expert-evaluator

HOW TO REGISTER AS AN EXPERT

The registration in the EC experts' database is essential for the Commission services to be able to issue an invitation to evaluate submitted proposals or to review ongoing projects. Without the valid registration the EC services **will not be able** to produce your contract.

To register you need to go to the **Participant Portal**


<http://ec.europa.eu/research/participants/portal/desktop/en/home.html>

The registration is two-tier:

- 1) creation of an ECAS account (used also for other roles, for example a project coordinator)
- 2) registration as an expert.

1) ECAS account

You can create an ECAS European Commission's secure Authentication Service) account either by clicking on the 'register' button on the right hand side of the page



or by going to the experts tab

<http://ec.europa.eu/research/participants/portal/desktop/en/experts/index.html>

and clicking on **Create your Portal (ECAS) account** at the bottom of the page.

Once this is done, go back to the Expert area in the Participant Portal,

<http://ec.europa.eu/research/participants/portal/desktop/en/experts/index.html>

and log-in with your ECAS user name or email address and password by clicking on the Login button on the right hand side of the page



Login [Not registered yet](#)

Is the selected domain correct?
[External](#) [Change it](#)

Username or e-mail address *

unreal

Password *


••••••••

▶ [More options...](#)

Login!

[Lost your password?](#)

After a successful login you will be able to see your name where the Login button used to be.



<https://webgate.ec.europa.eu/fpfis/wikis/display/ECResearchGMS/Experts>

European Commission

RESEARCH & INNOVATION

Participant Portal

Espaces ▾ Personnes Suite ▾ Créer

Recherchez l'espace

Home Beneficiaries Experts Submission Grants Identity and Access Management H2020 Online Manual What's New Helpdesk and FAQ

/ H2020 IT Documentation

Experts

Surveiller Partager Outils ▾

This is the home page for all information on Expert tasks.

- Click the **Expert Registration, Contract Management and Contract Payments** tab for information on registering to work as an expert, signing and managing expert contracts, and submitting payment requests.
Click the **Expert Evaluation of Proposals** tab for information on how to use the evaluation tool to evaluate proposals remotely.

Expert Registration, Contract Management and Contract Payments Expert Evaluation of Proposals

This is the home page for the Expert Management in the Participant Portal space.

Table of Contents:

- [1. Introduction](#)
- › [2. Creating your Expert Profile](#)
- › [3. Managing Your Expert Contracts](#)
- › [4. Managing Your Payment Requests](#)

→ **Equality of treatment:**

all the proposals should be treated alike, considering only their merits.

→ **Input for proposal rejection or contract negotiation**

The comments associated with the scores are vital. To justify marks, help applicant understand, but also, if applicable, as means of improving successful proposals during negotiation.

→ **Selecting high quality:**

proposals selected for funding must demonstrate high scientific, technical and managerial quality.

As an evaluator, you must follow the “**Code of Conduct for independent experts appointed as evaluators**”

You **provide an impartial and clear opinion** on each proposal, and a prioritisation among them.

You must be:

- **Independent:** represent yourself, not your employer, or your country...
- **Objective:** evaluate the proposal as written
- **Accurate:** use the official evaluation criteria only
- **Consistent:** apply the same standard of judgment to each proposal
- **Incommunicado:** respect strict confidentiality on the proposals, the whole evaluation process and results, during and after the evaluation!

A global list of FP7 evaluators is published yearly on CORDIS

**Confidentiality:
the first principle of evaluation**

No information, results of the evaluation or documents should be communicated to anyone outside the consensus group.

Make sure that you delete all proposals and related information on your computers and/or destroy all paper copies.

NOT TO IGNORE – A VERY GOOD REIMBURSEMENT FOR YOUR WORK



Definition provided with appointment letter:

→ **Disqualifying COI**

- Involved in preparation of proposal
- Stands to benefit directly
- Close family relationship
- Director/trustee/partner
- Employee (*but, see exception...*)
- Member of Advisory Group
- Any other situation that compromises impartiality

→ **Potential COI**

- Employed by applicant in last 3 years
- Involved in research collaboration in previous 3 years
- Any other situation that casts doubt... or that could reasonably appear to do so...



HORIZON 2020

**Thank you
for your attention!**

Grigorij.kogan@ec.europa.eu

Find out more:

www.ec.europa/research/horizon2020